Norway· NO-ID_D81B2C7F-6BC8-4784-B7E2-D20E6CA437A7
Visudyne
A verteporfin product containing verteporfin, registered in Norway by Cheplapharm Arzneimittel GmbH. The same ATC class is registered in 15 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Verteporfin is registered in 15 of 19 countries.
Countries holding a registration under ATC S01LA01 (verteporfin), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 9 of them publish a price we can compare per daily dose
Verteporfin · ATC S01LA01
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Verteporfin
- Manufacturer
- Cheplapharm Arzneimittel GmbH
- Country
- Norway (NO)
- ATC code
- S01LA01
- ATC class
- Verteporfin
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_varenummer00261615NOK 23942.5
- no_merkevare_idID_D81B2C7F-6BC8-4784-B7E2-D20E6CA437A7
- gtin7612797029114
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
166 interactions on record for verteporfin.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Verteporfin · interactions on record
166 records
- 1 severe
- 144 moderate
- 2 minor
- 19 info
Most severe, free to view
- Aminolevulinic acidL01XD04severe
- TetracyclineA01AB13moderate
- DoxycyclineA01AB22moderate
- MinocyclineA01AB23moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Verteporfin in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandVisudyneOrifarm Oy
- United KingdomVerteporfin 15mg powder for solution for infusion vialsNeon Healthcare Ltd
- SpainVISUDYNE 15 MG POLVO PARA SOLUCION PARA PERFUSIONCheplapharm Arzneimittel Gmbh
- IrelandVisudyne 15 mg powder for solution for infusionCHEPLAPHARM Arzneimittel GmbH
- IcelandVisudyneCHEPLAPHARM Arzneimittel GmbH
- PolandVisudyneCHEPLAPHARM Arzneimittel GmbH
- BelgiumVisudyne 15 mgCheplapharm Arzneimittel
- SwedenVisudyne 15 mg Pulver till infusionsvätska, lösningCheplapharm Arzneimittel GmbH
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Visudyne
- Liechtenstein · Visudyne
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dd423bc6-ecc3-4122-8566-19d3ca70ca23 GET /v1/drugs/dd423bc6-ecc3-4122-8566-19d3ca70ca23?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Pulver til infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Verteporfin",
"merkevare_id": "ID_D81B2C7F-6BC8-4784-B7E2-D20E6CA437A7",
"name_form_strength": "Visudyne pulv til inf væske oppl 15 mg",
"prescription_group": "C"
}See everything about verteporfin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.